IN THE CLAIMS:

Claims 5, 23, and 25-27 have been amended herein, and new claims 30-35 have been added herewith. All claims currently pending and under consideration in the referenced application are shown below.

Listing of Claims:

1-4. (Canceled)

5. (Currently amended) A method of treating a patient for depression comprising administering to ~~said~~ the patient an effective amount of a compound having the following chemical structure:



wherein X^1 is either -Br, -Cl, -F, -I, $-CF_3$, alkyl, -OH, $-OCF_3$, -O-alkyl, or -O-acyl;
X^2 is either -Br, -Cl, -F, -I, $-CF_3$, alkyl, -OH, $-OCF_3$, -O-alkyl, or -O-acyl; and
R^3 is either -H or $-CH_3$;
or a pharmaceutically acceptable salt thereof.

6. (Original) The method of claim 5, wherein X^1 is -F, -Cl, $-OCF_3$ or $-CF_3$ and X^2 is either 2-OCH_3, 2-CH_3, 3-F, 3-CF_3, or 4-CF_3.

7-20. (Canceled)

21. (Previously presented) The method of claim 5, wherein X^1 and X^2 are F, and R^3 is –H.

22. (Previously presented) The method of claim 21, wherein X^2 is at the 3-position.

23. (Currently amended) The method of claim 5, wherein X^1 and X^2 are -F, and R^3 is -CH_3.

24. (Previously presented) The method of claim 23, wherein X^2 is at the 3-position.

25. (Currently amended) The method of claim 5, wherein ~~said~~ the compound is active at a serotonin reuptake site and at a N-methyl-D-aspartate (NMDA) receptor.

26. (Currently amended) The method of claim 5, wherein ~~said~~ the compound has an NMDA receptor IC_{50} of about 50 nM to about 1 μM.

27. (Currently amended) The method of claim 26, wherein ~~said~~ the compound has an NMDA receptor IC_{50} of about 100 nM to about 800 nM.

28. (Previously presented) The method of claim 5, wherein the compound has the chemical structure:



and pharmaceutically acceptable salts thereof.

29. (Previously presented) The method of claim 27, wherein the compound has the chemical structure:



and pharmaceutically acceptable salts thereof.

30. (New) A method of treating a patient for depression comprising administering to said patient an effective amount of a compound selected from the group consisting of:


,

,

,

,

;

and pharmaceutically acceptable salts thereof.

31. (New) The method according to claim 30 wherein the compound is



and pharmaceutically acceptable salts thereof.

32. (New) The method according to claim 30 wherein the compound is



and pharmaceutically acceptable salts thereof.

33. (New) The method according to claim 30 wherein the compound is



and pharmaceutically acceptable salts thereof.

34. (New) The method according to claim 30 wherein the compound is



and pharmaceutically acceptable salts thereof.

35. (New) The method according to claim 30 wherein the compound is



and pharmaceutically acceptable salts thereof.